Your browser doesn't support javascript.
loading
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Singh, Shweta; Serwer, Laura; DuPage, Amy; Elkins, Kristi; Chauhan, Niharika; Ravn, Matthew; Buchanan, Fritz; Wang, Leyu; Krimm, Michael; Wong, Ken; Sagert, Jason; Tipton, Kimberly; Moore, Stephen J; Huang, Yuanhui; Jang, Andrew; Ureno, Eric; Miller, Adam; Patrick, Sarah; Duvur, Shanti; Liu, Shouchun; Vasiljeva, Olga; Li, Yingchun; Henriques, Tracy; Badagnani, Ilaria; Jeffries, Shawn; Schleyer, Siew; Leanna, Rob; Krebber, Claus; Viswanathan, Sridhar; Desnoyers, Luc; Terrett, Jonathan; Belvin, Marcia; Morgan-Lappe, Susan; Kavanaugh, W Michael; Richardson, Jennifer.
Afiliação
  • Singh S; CytomX Therapeutics, Inc, South San Francisco, California.
  • Serwer L; CytomX Therapeutics, Inc, South San Francisco, California.
  • DuPage A; CytomX Therapeutics, Inc, South San Francisco, California.
  • Elkins K; CytomX Therapeutics, Inc, South San Francisco, California.
  • Chauhan N; AbbVie Inc., North Chicago, Illinois.
  • Ravn M; AbbVie Inc., North Chicago, Illinois.
  • Buchanan F; AbbVie Inc., North Chicago, Illinois.
  • Wang L; AbbVie Inc., North Chicago, Illinois.
  • Krimm M; CytomX Therapeutics, Inc, South San Francisco, California.
  • Wong K; CytomX Therapeutics, Inc, South San Francisco, California.
  • Sagert J; CytomX Therapeutics, Inc, South San Francisco, California.
  • Tipton K; CytomX Therapeutics, Inc, South San Francisco, California.
  • Moore SJ; CytomX Therapeutics, Inc, South San Francisco, California.
  • Huang Y; CytomX Therapeutics, Inc, South San Francisco, California.
  • Jang A; CytomX Therapeutics, Inc, South San Francisco, California.
  • Ureno E; CytomX Therapeutics, Inc, South San Francisco, California.
  • Miller A; CytomX Therapeutics, Inc, South San Francisco, California.
  • Patrick S; CytomX Therapeutics, Inc, South San Francisco, California.
  • Duvur S; CytomX Therapeutics, Inc, South San Francisco, California.
  • Liu S; CytomX Therapeutics, Inc, South San Francisco, California.
  • Vasiljeva O; CytomX Therapeutics, Inc, South San Francisco, California.
  • Li Y; AbbVie Inc., North Chicago, Illinois.
  • Henriques T; AbbVie Inc., North Chicago, Illinois.
  • Badagnani I; AbbVie Inc., North Chicago, Illinois.
  • Jeffries S; AbbVie Inc., North Chicago, Illinois.
  • Schleyer S; CytomX Therapeutics, Inc, South San Francisco, California.
  • Leanna R; AbbVie Inc., North Chicago, Illinois.
  • Krebber C; CytomX Therapeutics, Inc, South San Francisco, California.
  • Viswanathan S; CytomX Therapeutics, Inc, South San Francisco, California.
  • Desnoyers L; CytomX Therapeutics, Inc, South San Francisco, California.
  • Terrett J; CytomX Therapeutics, Inc, South San Francisco, California.
  • Belvin M; CytomX Therapeutics, Inc, South San Francisco, California.
  • Morgan-Lappe S; AbbVie Inc., North Chicago, Illinois.
  • Kavanaugh WM; CytomX Therapeutics, Inc, South San Francisco, California.
  • Richardson J; CytomX Therapeutics, Inc, South San Francisco, California.
Mol Cancer Ther ; 21(8): 1326-1336, 2022 08 02.
Article em En | MEDLINE | ID: mdl-35666803
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoconjugados / Neoplasias / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoconjugados / Neoplasias / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2022 Tipo de documento: Article